Metagenomi Therapeutics EBITDA 2022-2025 | MGX
Metagenomi Therapeutics ebitda from 2022 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
|
Metagenomi Therapeutics Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $-91 |
| 2023 | $-83 |
| 2022 | $-44 |
| 2021 | $-23 |
|
Metagenomi Therapeutics Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-09-30 | $-22 |
| 2025-06-30 | $-20 |
| 2025-03-31 | $-28 |
| 2024-12-31 | $-21 |
| 2024-09-30 | $-24 |
| 2024-06-30 | $-18 |
| 2024-03-31 | $-29 |
| 2023-12-31 | $-21 |
| 2023-09-30 | $-24 |
| 2023-06-30 | $-20 |
| 2023-03-31 | $-19 |
| 2022-12-31 | |
| 2021-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.055B | $0.052B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $38.974B | 12.09 |
| BridgeBio Pharma (BBIO) | United States | $14.501B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.806B | 18.36 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.915B | 23.87 |
| Bausch Health Cos (BHC) | Canada | $2.222B | 1.58 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.310B | 9.44 |
| Taysha Gene Therapies (TSHA) | United States | $1.246B | 0.00 |
| Personalis (PSNL) | United States | $0.729B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.422B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.187B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |